HS
LAB icon

HighVista Strategies’s Standard BioTools LAB Stock Holding History

HighVista Strategies’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,000
Closed -$66K – 135
2020
Q4 		$66K Hold
11,000
– – 0.04% 110
2020
Q3 		$82K Buy
+11,000
New +$75.9K 0.06% 90
2020
Q2 		– Sell
-23,800
Closed -$60K – 109
2020
Q1 		$60K Hold
23,800
– – 0.06% 38
2019
Q4 		$83K Buy
+23,800
New +$83.7K 0.06% 91

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HighVista Strategies's LAB Position: Q1 2021 in Review

HighVista Strategies sold out of Standard BioTools (LAB) in Q1 2021, closing a stake of 11,000 shares — an estimated $66K sold.

HighVista Strategies first reported a position in LAB in Q4 2019 and held it in 4 quarters. The position peaked at $83K in Q4 2019. 138 funds tracked by Wall St. Rank hold LAB as of Q1 2021.

  • HighVista Strategies reported no remaining Standard BioTools position as of Q1 2021 after selling out during the quarter.
  • HighVista Strategies sold 11,000 Standard BioTools shares in Q1 2021, an estimated $66K.
  • HighVista Strategies first reported a position in Standard BioTools in Q4 2019 and held it in 4 quarters.
  • HighVista Strategies's Standard BioTools position peaked at $83K in Q4 2019.
  • 138 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2021.

Based on HighVista Strategies's 13F filing for Q1 2021, filed 17 May 2021.